BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Wednesday, April 24, 2024
See today's BioWorld Asia
Home
» CSPC acquires stake in YZY through $55M deal; gains bispecific antibodies
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
CSPC acquires stake in YZY through $55M deal; gains bispecific antibodies
Jan. 17, 2018
By
David Ho
No Comments
HONG KONG – CSPC Pharmaceutical Group Ltd., of Shijiazhuang, China, has made plans to acquire a 39.56 percent stake in Wuhan YZY Biopharma Co. Ltd. in a deal worth up to ¥356 million (US$54.6 million).
BioWorld Asia